Opthea Limited (OPT.AX)

0,6800 +0,0450 (+7,09%) Al cierre: 04:10PM AEST

Opthea Limited

650 Chapel Street
Suite 0403 Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399
https://opthea.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 24

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.	Founder, Chief Innovation Officer & Executive Director	911,93k	N/A	1975
Ms. Judith J. Robertson B.A., M.B.A.	Chief Commercial Officer	894,99k	N/A	1961
Ms. Karen Adams CPA	VP of Finance & Company Secretary	463,99k	N/A	1972
Dr. Frederic Guerard M.S., Pharm.D.	Chief Executive Officer	N/A	N/A	1973
Mr. Peter F. Lang M.B.A.	Chief Financial Officer	N/A	N/A	1973
Ms. Sarika Gulhar Ph.D.	Executive Director of Human Resources	N/A	N/A	N/A
Dr. Michael Gerometta Ph.D.	Head of Chemistry, Manufacturing & Controls Development	199,09k	N/A	1965
Mr. Bruno Gagnon BPHARM, M.Sc.	Senior Vice President of Global Clinical Operations	N/A	N/A	1969
Dr. Kenneth Sall	Chief Medical Officer	N/A	N/A	N/A
Dr. Fang Li Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en AUD.

Descripción

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Gobierno corporativo

El ISS Governance QualityScore de Opthea Limited, a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 10; Tablero: 6; Derechos de los accionistas: 10; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.